Curran Simpson - 01 Jan 2022 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role: Chief Oper. & Tech. Officer
Signature: /s/ Patrick J. Christmas as attorney-in-fact
Issuer symbol: RGNX
Transactions as of: 01 Jan 2022
Net transactions value: -$43,556
Form type: 4
Filing time: 04 Jan 2022, 20:06:14 UTC
Next filing: 05 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RGNX	Common Stock	Tax liability	$43,556	-1,332	-7.5%	$32.70	16,416	01 Jan 2022	Direct
transaction	RGNX	Common Stock	Award	$0	+10,700	+65%	$0.000000	27,116	03 Jan 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RGNX	Stock Option (Right to Buy)	Award	$0	+51,100		$0.000000	51,100	03 Jan 2022	Common Stock	51,100	$34.31	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026 while the recipient provides continuous service to the Issuer.
F2	25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer.